Literature DB >> 1544702

Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells.

M T Dimanche-Boitrel1, H Pelletier, P Genne, J M Petit, C Le Grimellec, P Canal, C Ardiet, G Bastian, B Chauffert.   

Abstract

In vitro sensitivity of HT29 human colon cancer cells to doxorubicin (DXR), vincristine (VCR), etoposide (VP16), cisplatin (CDDP), melphalan (L-PAM) and 5-fluorouracil (5FU) was markedly reduced when cell-culture density increased. For some drugs, confluence-dependent resistance (CDR) was partly due to decreased intracellular drug accumulation; the ratio of mean intracellular drug content of non confluent to confluent cells (NC/C) was 2.5 for DXR, 4.1 for VCR and 7.4 for VP16. Altered drug penetration with confluence could be related to decrease of plasma membrane fluidity as measured by the fluorescence polarization method. Reduction of drug intracellular accumulation was nil or weak for L-PAM (NC/C = 1.0), CDDP (NC/C = 1.2) and 5 FU (NC/C = 1.8). Even if drug concentration was adjusted in culture medium to produce similar intracellular drug content in confluent and non confluent cells, higher intrinsic resistance of confluent cells was still evidenced for DXR and VP16 but not for VCR, the only agent without direct interaction with DNA. DXR- and VP16-induced DNA breakage was also less important in confluent than in non-confluent cells. CDR appeared closely related to an increased proportion of non-cycling cells at confluence, as demonstrated by flow cytometry, expression of nuclear antigen recognized by Ki67 MAb and expression of topoisomerase II. CDR is probably a major factor in the poor sensitivity of colorectal adenocarcinomas to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544702     DOI: 10.1002/ijc.2910500502

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  21 in total

1.  Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.

Authors:  Hiroaki Itamochi; Misaki Kato; Mayumi Nishimura; Nao Oumi; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Jun Naniwa; Seiya Sato; Michiko Nonaka; Akiko Kudoh; Naoki Terakawa; Junzo Kigawa; Tasuku Harada
Journal:  Hum Cell       Date:  2013-02-21       Impact factor: 4.174

2.  Multiwell stiffness assay for the study of cell responsiveness to cytotoxic drugs.

Authors:  Silviya Zustiak; Ralph Nossal; Dan L Sackett
Journal:  Biotechnol Bioeng       Date:  2013-09-06       Impact factor: 4.530

3.  Establishment and characterization of a novel ovarian clear cell carcinoma cell line, TU-OC-2, with loss of ARID1A expression.

Authors:  Seiya Sato; Hiroaki Itamochi; Nao Oumi; Youhei Chiba; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Jun Chikumi; Michiko Nonaka; Akiko Kudoh; Hiroaki Komatsu; Tasuku Harada; Toru Sugiyama
Journal:  Hum Cell       Date:  2016-03-09       Impact factor: 4.174

Review 4.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

5.  Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.

Authors:  Hiroaki Itamochi; Misaki Kato; Mayumi Nishimura; Tetsuro Oishi; Muneaki Shimada; Shinya Sato; Jun Naniwa; Seiya Sato; Michiko Nonaka; Akiko Kudoh; Naoki Terakawa; Junzo Kigawa; Tasuku Harada
Journal:  Hum Cell       Date:  2012-12-30       Impact factor: 4.174

6.  Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

Authors:  Xin-Yan Pei; Yun Dai; Leena E Youssefian; Shuang Chen; Wesley W Bodie; Yukie Takabatake; Jessica Felthousen; Jorge A Almenara; Lora B Kramer; Paul Dent; Steven Grant
Journal:  Blood       Date:  2011-09-12       Impact factor: 22.113

7.  Influence of cytokines on mdr1 expression in human colon carcinoma cell lines: increased cytotoxicity of MDR relevant drugs.

Authors:  W Walther; U Stein
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 8.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 9.  Kinetic resistance to anticancer agents.

Authors:  M T Dimanche-Boitrel; C Garrido; B Chauffert
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

10.  Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.

Authors:  Jin Song; Ie-ming Shih; Daniel W Chan; Zhen Zhang
Journal:  Neoplasia       Date:  2009-06       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.